By Greg Kulnis - Vice President, Customer Solutions (Infectious Disease) for Nexelis The Covid-19 pandemic has led to unprecedented collaboration and acceleration in vaccine development. In the past two years, many leading pharmaceutical and biotech companies have shifted their research and development (R&D) focus to tackle the threat of SARS-CoV-2. Companies have needed to rapidly […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!